Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors and status of novel antivirals, 2016–2017
Angie Lackenby,Terry G. Besselaar,Rod S. Daniels,Alicia M. Fry,Vicki Gregory,Larisa V. Gubareva,Weijuan Huang,Aeron C. Hurt,Sook-Kwan Leang,Raphael T.C. Lee,Janice Lo,Lori Lollis,Sebastian Maurer-Stroh,Takato Odagiri,Dmitriy Pereyaslov,Emi Takashita,Dayan Wang,Wenqing Zhang,Adam Meijer +18 more
TLDR
This 2016/17 analysis demonstrates that neuraminidase inhibitors remain suitable for treatment and prophylaxis of influenza virus infections, but continued monitoring is important.About:
This article is published in Antiviral Research.The article was published on 2018-07-03 and is currently open access. It has received 134 citations till now. The article focuses on the topics: Neuraminidase inhibitor & Zanamivir.read more
Citations
More filters
Journal ArticleDOI
Influenza and antiviral resistance: an overview
TL;DR: There is evidence to suggest that these resistant strains (particularly H1N1 pdm09) are able to maintain their replicative fitness and transmissibility, although there is no clear evidence that being infected with a resistant strain is associated with a worse clinical outcome.
Journal ArticleDOI
Advances in respiratory virus therapeutics – A meeting report from the 6th isirv Antiviral Group conference
John H. Beigel,Hannah H. Nam,Peter L. Adams,Amy E. Krafft,William L. Ince,Samer S. El-Kamary,Amy C. Sims +6 more
TL;DR: The aim of this report is to provide a summary of the presentations given at the 6th Antiviral Group conference in Rockville, Maryland, November 13–15, 2018.
Journal ArticleDOI
Treatment-Emergent Influenza Variant Viruses With Reduced Baloxavir Susceptibility: Impact on Clinical and Virologic Outcomes in Uncomplicated Influenza.
Takeki Uehara,Frederick G. Hayden,Keiko Kawaguchi,Shinya Omoto,Aeron C. Hurt,Menno D. de Jong,Nobuo Hirotsu,Norio Sugaya,Nelson Lee,Keiko Baba,Takao Shishido,Kenji Tsuchiya,Simon Portsmouth,Hiroshi Kida +13 more
TL;DR: The emergence of viruses with PA/I38X substitutions following baloxavir treatment was associated with transient rises in infectious virus titers, prolongation of virus detectability, initial delay in symptom alleviation, and uncommonly with symptom rebound.
Journal ArticleDOI
Antivirals targeting the polymerase complex of influenza viruses.
TL;DR: Four compounds which inhibit polymerase function, baloxavir marboxil, favipiravir, pimodivir and AL-794 are discussed and their clinical and virological effectiveness are discussed, their propensity to select for resistance and their potential for future combination therapy with the most commonly used neuraminidase inhibitor, oseltamivir.
Journal ArticleDOI
Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2017-2018.
Emi Takashita,Rod S. Daniels,Seiichiro Fujisaki,Vicki Gregory,Larisa V. Gubareva,Weiijuan Huang,Aeron C. Hurt,Angie Lackenby,Ha T. Nguyen,Dmitriy Pereyaslov,Merryn Roe,Magdi Samaan,Kanta Subbarao,Herman Tse,Dayan Wang,Hui-Ling Yen,Wenqing Zhang,Adam Meijer +17 more
TL;DR: Overall, in the 2017-18 period the frequency of circulating influenza viruses with reduced susceptibility to NAIs or baloxavir was low, but continued monitoring is important.
References
More filters
Journal ArticleDOI
Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern
Rick A. Bright,Marie-Jo Medina,Xiyan Xu,Gilda I. Perez-Oronoz,Teresa R. Wallis,Xiaohong M. Davis,Laura Povinelli,Nancy J. Cox,Alexander Klimov +8 more
TL;DR: The authors' data raise concerns about the appropriate use of adamantanes and draw attention to the importance of tracking the emergence and spread of drug-resistant influenza A viruses.
Journal ArticleDOI
Surveillance for Neuraminidase Inhibitor Resistance among Human Influenza A and B Viruses Circulating Worldwide from 2004 to 2008
Tiffany G. Sheu,Varough M. Deyde,Margaret Okomo-Adhiambo,Rebecca Garten,Xiyan Xu,Rick A. Bright,Eboneé N. Butler,Teresa R. Wallis,Alexander Klimov,Larisa V. Gubareva +9 more
TL;DR: The recent increase in oseltamivir resistance among A(H1N1) viruses isolated from untreated patients raises public health concerns and necessitates close monitoring of resistance to NA inhibitors.
Journal ArticleDOI
Evidence for Zanamivir Resistance in an Immunocompromised Child Infected with Influenza B Virus
Larisa V. Gubareva,Mikhail Matrosovich,Malcolm K. Brenner,Richard C. Bethell,Robert G. Webster +4 more
TL;DR: The data indicate that the current methods for monitoring resistant mutants are potentially flawed because no tissue culture system adequately reflects the receptor specificity of human respiratory tract epithelium.
Journal ArticleDOI
Detection of Influenza Viruses Resistant to Neuraminidase Inhibitors in Global Surveillance during the First 3 Years of Their Use
Arnold S. Monto,Jennifer L. McKimm-Breschkin,Catherine A. Macken,Alan W. Hampson,Alan J. Hay,Alexander Klimov,Masato Tashiro,Robert G. Webster,Michelle Aymard,Frederick G. Hayden,Maria Zambon +10 more
TL;DR: The frequency of variants with decreased sensitivity to the NAIs did not increase significantly during this period, but continued surveillance is required, especially in regions with higher NAI use.
Journal ArticleDOI
Recovery of drug-resistant influenza virus from immunocompromised patients: a case series.
TL;DR: In this paper, the authors describe a novel Asp198Asn NA mutation in an influenza B virus and its decreased susceptibility to both oseltamivirus and zanamivir.
Related Papers (5)
Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2014-2015
Adam Meijer,Helena Rebelo-de-Andrade,Helena Rebelo-de-Andrade,Vanessa Correia,Vanessa Correia,Terry G. Besselaar,Renu Drager-Dayal,Alicia M. Fry,V. Gregory,Larisa V. Gubareva,Tsutomu Kageyama,Angie Lackenby,Janice Lo,Takato Odagiri,Dmitriy Pereyaslov,Marilda M. Siqueira,Emi Takashita,Masato Tashiro,Dayan Wang,Sun Wong,Wenqing Zhang,Rod S. Daniels,Aeron C. Hurt +22 more